Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is supported by an educational grant from Sanofi Genzyme.
Oncology Briefings™: Best Practices for the Prevention and Management of Tumor Lysis Syndrome
Release Date: April 30, 2020
Expiration Date: April 30, 2021
Activity Overview
This online activity is designed to provide a concise and focused overview on an important clinical topic and includes information on the diagnosis and risk stratification of tumor lysis syndrome (TLS), evidence-based recommendations on the prophylaxis and treatment of TLS, and unmet medical needs in the management of TLS. The engaging, multimedia format of this program includes audio commentary from an expert thought leader integrated with text-based elements.
Acknowledgement of Support
This activity is supported by an educational grant from Sanofi Genzyme.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
This educational initiative is directed toward medical oncologists and hematologists who treat patients with hematologic malignancies. Nephrologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, fellows, and other healthcare professionals interested in the treatment and prevention of TLS will also be invited to participate.
Learning Objectives
Upon successful completion of this educational activity, you should be better prepared to:
- Identify risk factors in pediatric and adult patients who could potentially develop tumor lysis syndrome
- Describe optimal prophylactic strategies for patients with TLS based on individual risk
- Apply evidence-based recommendations for the treatment of TLS in patients with cancer
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Faculty
.jpg)
Director, Chronic Lymphocytic Leukemia Program
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Grant Research Support: Adaptive Biotechnologies, DTRM Biopharma, Johnson & Johnson, Loxo Oncology, Pharmacyclics, Regeneron, Sunesis, TG Therapeutics; Consultant: Adaptive, AstraZeneca, Celgene, Johnson & Johnson, Loxo Oncology, Pharmacyclics, Regeneron, Sunesis, TG Therapeutics.
The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
